Astrana Health: Record Numbers, a 22% Drawdown, and a Cyber Incident Nobody Will Size
The delegated-risk operator beat, held guidance, and re-cut its own revenue math — but Medicaid acuity, an unquantified breach, and an accounting transition are what the tape is pricing.
ASTH · Earnings Call · 2026-11-05
The beat the market declined to buy
Astrana Health's third quarter was, on the numbers, its best ever: revenue of $1.02 billion, up 7%; adjusted EBITDA of $77.2 million, up 13% and near the top of a $72.5–77.5 million guide; adjusted diluted EPS of $0.71. Nine-month free cash flow of roughly $105 million funded $116 million of debt paydown, pulling net leverage to about 2.2x against the 2.5x pro forma when Prospect closed. The Care Partners business is doing what management said it would — Texas cohorts maturing, medical cost trend "slightly better" than the ~5.2% embedded in guidance, G&A down to 6.2% of revenue year-to-date. And yet the stock enters this report down 21.7% over 90 days, in a single unbroken decline from a July 1 peak of $49.81. At 0.67x revenue, it is a business priced as though its revenue is low-quality and its balance sheet is fragile — a reading reinforced by $541 million of net debt and 2.1x interest coverage. That gap between operating reality and valuation is the whole dossier. The question is whether Q3 closed it or widened it.The new number that answers an awkward question
The single most company-unique thing on this call was an accounting invention: Premiums at Risk, or Gross Equivalent Consolidated Premiums. The reason is structural. ACO REACH, which sunsets at end-2026, lets Astrana book the full Medicare benchmark as revenue with medical costs in expenses; MSSP books only its share of savings, net. As the ACO program mix rotates toward net-basis arrangements and the new ACO LEAD model, reported revenue can shrink without a dollar of economics changing.Read that as an inoculation. Management is telling investors in advance not to confuse a GAAP revenue headwind with a business headwind — and CFSO Chan Basho's admission that "changes in our reported GAAP revenue won't reflect necessarily changes in the total Medicare spend we're managing" is the tell. This is a genuinely new disclosure for the company and, per the analyst on the line, the first time he had seen a peer do it. It also explains the curious keyword clustering this quarter around net basis and "apples to apples" — language of a company defending a denominator.We're introducing a supplemental measure: Gross Equivalent Consolidated Premiums, or Premiums at Risk... On this basis, we expect approximately $4.45 billion in premiums at risk for 2026, compared to our reported revenue guidance of $3.9 billion to $4 billion.
Medicaid stops being a footnote
The keyword ranking inside Astrana's own transcript moved decisively. membership attrition is now the top theme, replacing the full-risk conversion language that dominated the prior quarter. The specific change is acuity, and management said so plainly in a way it had not three months earlier: “Earlier this year, we said that we weren't seeing as much adverse selection as we expected. We're starting to see signs of that ticking up a bit, modest changes in the risk profile of the members that are remaining as the year progresses.” — Brandon Sim, President and Chief Executive Officer · 2026-11-05 Contrast that with August, when the same CEO described Medicaid as fully contained: “Medicaid is in line with that trend number, and that was inclusive of potential adverse selection effects in our guidance.” — Brandon Sim, CEO or Senior Executive · 2026-08-06 And with May, when he said trend had come in "better in Medicaid as well relative to our expectations" with "lower adverse selection." Three calls, three different reads on the same risk pool. That is the shift the tape has been pricing. The forward number is now explicit: “We've been incorporating these developments into our planning for some time and currently anticipate a 10% to 15% decline in Medicaid membership in 2027.” — Brandon Sim, President and Chief Executive Officer · 2026-11-05 With 10–20% of those members sitting in UIS status moving to fee-for-service, and work requirements plus redeterminations ahead, management guides a mid-single-digit net EBITDA headwind. This is not idiosyncratic — Medicaid work requirements sits on the market's 90-day advancers list, carried by MOH, UHS and MMS, which is a reminder that the policy variable is industry-wide even if the acuity outcome is Astrana's alone.What management won't quantify
Two items deserve the skeptical eyebrow. First, the September cybersecurity incident, which appeared in the Q&A and nowhere in the prepared remarks:No size, no timeline, no remediation date. For a company whose entire equity story rests on being a proprietary data and AI powered care enablement platform, an unpriced criminal breach of that platform is the risk the model cannot see. Second, the fourth-quarter range. Guidance of $48.5–61.5 million of adjusted EBITDA against $77.2 million in Q3 implies a wide band, and the answer was a rerun: “the wider range is really just, frankly, an artifact.” — Brandon Sim, President and Chief Executive Officer · 2026-11-05 In August the identical question got the identical word — “if you're focused on the width of the range, I think that's primarily an artifact.” — Brandon Sim, CEO or Senior Executive · 2026-08-06 Two consecutive quarters of "artifact" is a pattern, not a one-off. And the 2027 anchor has quietly migrated. On the May call the framing was “we continue to believe that the 2027 guide is within the range of outcomes” — Brandon Sim, President and Chief Executive Officer · 2026-05-08 — the $350 million EBITDA framework. In August it was reaffirmed as “mid to high teens EBITDA growth, not just for 2027, but into the medium term years as well.” — Brandon Sim, CEO or Senior Executive · 2026-08-06 Now it is "at least mid-teens" medium-term growth, with a verbal bridge built from new membership, rate-versus-trend and expansion markets, net of Medicaid. The target has become a rate, not a level.We experienced an incident and obviously involves criminal activity, and there's an ongoing investigation, including with law enforcement... I'm not sure it's extremely productive to speculate, you know, and get ahead of that process.